Fig. 2: PT pathologic features in patients with path-evaluable samples.
From: Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Pathologic features (histology, tumor PD-L1 status, tumor tissue TMB, LN involvement and TRAEs) for the path-evaluable population in the nivolumab plus chemotherapy (n = 141) and chemotherapy (n = 126) arms. LN involvement: yes indicates patients with pathologic evidence of LN disease at resection that had fully regressed (0% RVT) or had not regressed (>0% RVT) after neoadjuvant treatment. NA, not available. aMedian %RVT for nivolumab plus chemotherapy was 10.0% (squamous), 10.0% (nonsquamous), 35.0% (PD-L1 < 1%), 8.0% (PD-L1 1–49%), 0 (PD-L1 ≥ 50%), 30.0% (PD-L1 NA), 40.0% (TMB < 12.3 mut/Mb), 1.0% (TMB ≥ 12.3 mut/Mb), 10.0% (TMB NA), 35.0% (LN involvement), 1.0% (no LN involvement), 10.0% (TRAEs tissue grade 1/2), 23.0% (TRAEs grade 3/4) and 5.0% (No TRAE). bMedian %RVT for chemotherapy was 56.0% (squamous), 88.0% (nonsquamous), 69.0% (PD-L1 < 1%), 81.0% (PD-L1 1–49%), 60.0% (PD-L1 ≥ 50%), 94.0% (PD-L1 NA), 76.0% (TMB < 12.3 mut/Mb), 56.0% (TMB ≥ 12.3 mut/Mb), 77.0% (TMB NA), 82.5% (LN involvement), 62.5% (no LN involvement), 75.0% (TRAEs grade 1/2), 65.0% (TRAEs grade 3/4) and 90.5% (No TRAE).
